^
Association details:
| Biomarker: | CLDN18.2 expression |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Vyloy (zolbetuximab-clzb) (CLDN18.2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
Excerpt:
...- CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample....
Trial ID:
Source:
Title:
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
Excerpt:
...- CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample....
Trial ID:
More C2 evidence
Source:
Title:
Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer
Excerpt:
...- CLDN18.2 expression of the biopsy material from the cancer confirmed by immunohistochemistry...
Trial ID:
Less C2 evidence
Source:
Title:
FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
Published date:
02/18/2021
Excerpt:
The FAST study enrolled advanced gastric/gastro-oesophageal junction (G/GEJ) and oesophageal adenocarcinoma (EC) patients (≥18 years) with moderate-to-strong CLDN18.2 expression in ≥40% tumour cells….zolbetuximab+EOX...In the overall population, both PFS (HR=0.44; 95% CI, 0.29–0.67; P<0.0005) and OS (HR=0.55; 95% CI, 0.39–0.77; P<0.0005) were significantly improved with zolbetuximab+EOX (Arm 2) compared with EOX alone (Arm 1).
Secondary therapy:
EOX
DOI:
10.1016/j.annonc.2021.02.005
Trial ID:
